It really is very hard to understand why the mild trial is only 75 patients and the severe is 390. Obviously the mild trial is p2 and severe is p2/3 but I would think a patient that has severe symptoms needs a drug ASAP, why push the moderate trial as fast as possible? It is better in a way to get approval for moderate so those patients do not become severe cases. Maybe Mexico agrees and wants to do an accelerated severe trial to get it done faster than the FDA? I still think the data we have now will be strong enough for the FDA to approve for all use. Just trying to understand the reasoning.